Empowered Patient Podcast

Steve Glover, Co-founder and CEO of ZyVersa Therapeutics, focuses on rare kidney diseases and diseases with an inflammation component. Inflammasomes, the first response in the innate immune system, create an inflammation cascade.  The ZyVersa approach targets multiple inflammasomes to address diseases caused by the malfunction of this response. Steve explains, "Inflammation drives a lot of different diseases. And as we get into this a little bit more today, it's everything from kidney disease such as rare diseases such as FSGS and Alport syndrome and diabetic kidney disease all have an inflammation component. And in addition to that, when you look at diseases like Alzheimer's or MS, or Parkinson's, they're inflammation driven as well. So there is a connection between the two disease classes." "I've been in the industry a long time, and every so often the industry finds a new interesting discovery, and inflammasomes are clearly one of those new discoveries. In fact, one of the things I talk about quite a bit